Curative therapy of cardiac tachyarrhythmias with catheter ablation--a review of the experience with the first 1000 patients.
Cardiac tachyarrhythmias present as supraventricular or ventricular tachycardia. Catheter ablation has completely revolutionised the treatment of patients with these arrhythmias. We reviewed the experience of radiofrequency catheter ablation in a single centre. A total of 1,022 patients underwent radiofrequency catheter ablation from October 1991-December 1997. There were 480 patients who had AV nodal re-entrant tachycardia, 429 patients with accessory pathways, 7 patients with both AV nodal re-entrant tachycardia and accessory pathways, 4 patients with both AV nodal re-entrant tachycardia and atrial tachycardia. Twenty-seven patients had atrial tachycardia ablation, 28 had atrial flutter ablation and 11 patients had AV node ablation for atrial fibrillation. The mean age of the supraventricular tachycardia patients was 41 +/- 15 years (10-80 years). The mean duration of procedure was 108 +/- 60 minutes (15 to 480 minutes) and the mean fluoroscopy time was 19 +/- 17 minutes (3-122 minutes). Another 14 patients had ablation for right ventricular outflow tract ventricular tachycardia and 22 patients had ablation for idiopathic left ventricular tachycardia. The mean age of the ventricular tachycardia patients was 35 +/- 14 years (19-65 years). The mean duration of the ventricular tachycardia ablation procedure was 185 +/- 63 minutes (110-285 minutes) and the duration of fluoroscopy was 33 +/- 16 minutes (range 14-68 minutes). Of the 1,022 patients, 1,002 (98%) of the patients were successfully ablated. There were significant complications in less than 1% of the patients and no mortality associated with the procedure. The recurrence rate was 5% and could be successfully reablated when the procedure was repeated. Radiofrequency catheter ablation is thus an extremely safe and successful procedure and has replaced drug therapy as the treatment of choice for patients with supraventricular tachycardia and non-ischaemic ventricular tachycardia. It provides curative therapy without the need for life-long drug therapy.